Tralokinumab safe and effective in treating atopic dermatitis: JAMA

A new study published in the Journal of American Medical Association suggests that when used to treat adolescents with moderate to severe atopic dermatitis (AD), tralokinumab was effective and well tolerated.

Up to 20% of kids have atopic dermatitis, which often starts in early infancy. Recurrent eczematous skin lesions and severe itching are its defining features, and it can also cause anxiety, despair, and a worse quality of life. Adolescents with AD experience extra challenges, such as psychological effects on familial, social, and academic functioning. In order to assess the effectiveness and safety of tralokinumab monotherapy, an interleukin-13-targeted medication, in AD adolescents, Amy Paller and colleagues undertook this research.

The double-blinded, randomized, placebo-controlled, 52-week phase 3 ECZTRA 6 study took place at 72 facilities in 10 nations in North America, Europe, Asia, and Australia from July 17, 2018, to March 16, 2021. Patients with moderate to severe AD between the ages of 12 and 17 were enrolled. Every two weeks for 16 weeks, patients were randomly assigned (1:1:1) to receive tralokinumab (150 or 300 mg) or a placebo. Patients who had an IGA score of 0 (clear) or 1 (nearly clear) and/or an improvement in EASI score of 75% or greater (EASI 75) at week 16 without rescue medicine got maintenance therapy; other patients went to open-label tralokinumab, 300 mg every two weeks. Achieving an EASI score of 75 or receiving an IGA score of 0 or 1 were the main end points in week 16.